Table 2 Distribution of patient characteristics by treatment assignment.

From: Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study

 

E. coli-asparaginase (n = 50)

PEG-asparaginase (n = 72)

Median age (range), years

27 (18–35)

26 (18–35)

WBC, median (range) × 109/L

26.25 (0.50–94.06)

26.92 (1.08–99.74)

Age, n (%)

 18–26 years

24 (48.0)

37 (51.4)

 27–35 years

26 (52.0)

35 (48.6)

Sex, n (%)

 Male

37 (74.0)

47 (65.3)

 Female

13 (26.0)

25 (34.7)

Immunophenotype, n (%)

 B

37 (74.0)

49 (68.1)

 T

13 (26.0)

23 (31.9)

ECOG performance status, n (%)

 0–1 scores

38 (76.0)

57 (79.2)

  ≥ 2 scores

12 (24.0)

15 (20.8)

CSF, n (%)

 Positive

0 (0.0)

0 (0.0)

 Negative

50 (100.0)

72 (100.0)

Organ involvement, n (%)

 Mediastinal mass

11 (22.0)

16 (22.2)

 Hepatomegaly

7 (14.0)

11 (15.3)

 Splenomegaly

6 (12.0)

14 (19.4)

 Lymphadenopathy

10 (20.0)

13 (18.1)

  1. Abbreviations: E. coli-asparaginase, Escherichia coli asparaginase; PEG-asparaginase, polyethylene glycol-conjugated asparaginase; WBC, white blood cell; ECOG, Eastern Cooperative Oncology Group; CSF, cerebrospinal fluid.
Back to article page